The American Gastroenterological Association issued guideline updates on managing metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease, as well as surveillance for pancreatic cystic lesions and hepatocellular carcinoma in older adults, according to a MedPage Today roundup.
In chronic hepatitis delta, the phase III portion of the AZURE-1 trial testing investigational brelovitug met its primary endpoint of virologic response and alanine aminotransferase normalization, drugmaker Mirum Pharmaceuticals reported. Separately, a phase II trial of tipelukast showed promising safety and efficacy for hypertriglyceridemia and MASLD with type 2 diabetes.
For ulcerative colitis, a five-year analysis found that patients who started first-line vedolizumab spent more time with corticosteroid-free disease than those starting on a TNF inhibitor. In TNF-exposed patients, retrospective data favored upadacitinib over vedolizumab for effectiveness, but with more adverse events.